Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing Trk
US9428510B2 · kind B2 · utility
0Cited by
0References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 29, 2013 |
| Grant date | Aug 30, 2016 |
| Priority date | — |
| Expiry date | Aug 28, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a compound of following formula (I) or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, as well as pharmaceutical composition comprising such a compound, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.